该局人用药品委员会(CHMP)的结论认为，吡罗昔康的益处仍大于其风险，但是，基于安全方面的考虑，其应用仅限于某些特定的适应症。
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that piroxicam's benefits still outweigh its risks, but, based on safety grounds, only in certain, limited indications.
该局人用药品委员会(CHMP)的结论认为，吡罗昔康的益处仍大于其风险，但是，基于安全方面的考虑，其应用仅限于某些特定的适应症。
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that piroxicam's benefits still outweigh its risks, but, based on safety grounds, only in certain, limited indications.
应用推荐